Skip to content

Effect of Synbiotics in Critically Ill Patients

Synbiotic Intervention in Mechanically Ventilated Patients: Impact on Clinical outcomes and Gut-Lung Axis. An open label, randomized controlled trial - NIL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/01/101108
Enrollment
106
Registered
2026-01-14
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J958- Other intraoperative and postprocedural complications and disorders of respiratory system, not elsewhere classified

Interventions

Intervention1: SYNBIOTICS + Standard Care: Synbiotic therapy (Lactobacillus, Bifidobacterium, and the prebiotic fructooligosaccharide) administered twice daily enterally via nasogastric tube for 28 d

Sponsors

Dr Praveen Punniyamurthy
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients receiving enteral nutrition via a nasogastric tube. Patients hospitalized with conditions such as trauma, stroke, sepsis, or other indications necessitating mechanical ventilation. Patients who either did not receive antibiotics or received prophylactic antibiotics for less than 48 hours prior to intubation

Exclusion criteria

Exclusion criteria: Patients with known immunosuppressive conditions (e.g., HIV/AIDS, malignancy, post-transplant status). Patients currently receiving, or having received within the past 3 months, corticosteroids, immunosuppressive agents, or chemotherapy. History of bowel surgery. Presence of malabsorption syndromes or short bowel syndrome History of synbiotic use within the past 1 month. Patients receiving end-stage or palliative care Known allergy or hypersensitivity to synbiotic components. Any contraindications to enteral (nasogastric) administration. Legally authorized representatives unwilling or unable to provide written informed consent. Patients who received antibiotics for more than 48 hours prior to intubation

Design outcomes

Primary

MeasureTime frame
Incidence of Ventilator-Associated Pneumonia (VAP) (diagnosed using Modified Clinical Pulmonary Infection Score) Incidence of enteritis Timepoint: The study intervention will continue until extubation or a maximum of 28 days. Patients will be assessed daily while in the ICU and outcomes captured until ICU discharge or death

Secondary

MeasureTime frame
Duration of mechanical ventilation (in days) Length of ICU stay (in days) All cause ICU mortality Changes in Glasgow Coma Scale (GCS) scores Body temperature trends as a clinical marker of infection Changes in oxygenation status assessed by PaO2 & FiO2 ratio In cases of suspected infection, relevant investigations such as laboratory tests, chest X-rays, & computed tomography (CT) scans will be performed as clinically indicated Timepoint: The study intervention will continue until extubation or a maximum of 28 days. Patients will be assessed daily while in the ICU & outcomes captured until ICU discharge or death

Countries

India

Contacts

Public ContactDr Praveen Punniyamurthy

SRM medical college hospital research institute, Kattankulathur, Chengalpattu

jerinj@srmist.edu.in8248222321

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026